The estimated Net Worth of Steve Hoffman is at least $14.3 Milhão dollars as of 21 June 2022. Mr. Hoffman owns over 156,250 units of Tyme Technologies Inc stock worth over $6,206,995 and over the last 7 years he sold TYME stock worth over $7,142,708. In addition, he makes $900,789 as Chairman of the Board, Chief Executive Officer, e Chief Science Officer at Tyme Technologies Inc.
Steve has made over 56 trades of the Tyme Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 156,250 units of TYME stock worth $42,188 on 21 June 2022.
The largest trade he's ever made was selling 500,000 units of Tyme Technologies Inc stock on 11 December 2020 worth over $615,000. On average, Steve trades about 116,550 units every 29 days since 2017. As of 21 June 2022 he still owns at least 20,022,566 units of Tyme Technologies Inc stock.
You can see the complete history of Mr. Hoffman stock trades at the bottom of the page.
Steve Hoffman serves as Chairman of the Board, Chief Executive Officer, Chief Science Officer of the Company. He has been Chief Executive Officer and Chief Science Officer of the Company since March 2015. In these roles, Mr. Hoffman continues to supervise the development of our product candidates that he began with Tyme, Inc. and Luminant Biosciences, LLC (“Luminant”), wholly-owned subsidiaries of the Company. Prior to the establishment of Luminant in 2011, he held a variety of senior management positions with companies in the chemistry, aerospace and laser optics fields for over 25 years. Mr. Hoffman was a co-founder and, from 1993 to 2007, Chief Technology Officer of Mikronite Technologies Group Inc., a developer, licensor and marketer of material surfacing technologies for various manufacturing processes and applications. At Mikronite, Mr. Hoffman supervised its implementation of proprietary technology. His efforts on behalf of Mikronite were recognized by The Home Depot and Lowe’s with a Best New Product award and an Innovative Technology award from the New Jersey Manufacturers Association. Mr. Hoffman attended New York University and Rutgers University with a concentration in mechanical engineering from 1980 to 1984 and continued his studies under the direct supervision of the chairman of the physics department at the University of Michigan specializing in physics and electro-optics.
As the Chairman of the Board, Chief Executive Officer, e Chief Science Officer of Tyme Technologies Inc, the total compensation of Steve Hoffman at Tyme Technologies Inc is $900,789. There are 2 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.
Steve Hoffman is 57, he's been the Chairman of the Board, Chief Executive Officer, e Chief Science Officer of Tyme Technologies Inc since 2015. There are 10 older and 5 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.
Steve's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.
Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian, eDouglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
Tyme Technologies Inc executives and other stock owners filed with the SEC include: